{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:47:09Z","timestamp":1785768429806,"version":"3.56.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Finerenone, a selective, non-steroidal mineralocorticoid receptor antagonist, improves cardiovascular (CV) and kidney outcomes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). This subgroup analysis of FIDELITY, a pre-specified, pooled, individual patient-data analysis of FIDELIO-DKD (NCT02540993) and FIGARO-DKD (NCT02545049), compared finerenone vs. placebo in patients with and without baseline history of atherosclerotic CV disease (ASCVD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>Outcomes included a composite CV outcome [CV death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for heart failure (HHF)]; CV death or HHF; a composite kidney outcome (kidney failure, sustained estimated glomerular filtration rate decrease\u00a0\u226557%, or kidney-related death); all-cause mortality; and safety by baseline history of ASCVD.<\/jats:p>\n                  <jats:p>Of 13\u2009026 patients, 5935 (45.6%) had a history of ASCVD. The incidence of the composite CV outcome, CV death or HHF, and all-cause mortality was higher in patients with ASCVD vs. those without, with no difference between groups in the composite kidney outcome. Finerenone consistently reduced outcomes vs. placebo in patients with and without ASCVD (P-interaction for the composite CV outcome, CV death or HHF, the composite kidney outcome, and all-cause mortality 0.38, 0.68, 0.33, and 0.38, respectively). Investigator-reported treatment-emergent adverse events were consistent between treatment arms across ASCVD subgroups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Finerenone reduced the risk of CV and kidney outcomes consistently across the spectrum of CKD in patients with T2D, irrespective of prevalent ASCVD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvac054","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T18:50:17Z","timestamp":1666032617000},"page":"85-93","source":"Crossref","is-referenced-by-count":29,"title":["Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5640-0332","authenticated-orcid":false,"given":"Gerasimos","family":"Filippatos","sequence":"first","affiliation":[{"name":"Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Attikon University Hospital , Athens, Chaidari 12462 , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0805-8683","authenticated-orcid":false,"given":"Stefan D","family":"Anker","sequence":"additional","affiliation":[{"name":"Department of Cardiology (CVK), and Berlin Institute of Health Center for Regenerative Therapies, German Centre for Cardiovascular Research Partner Site Berlin, Charit\u00e9 Universit\u00e4tsmedizin , 10117 Berlin , Germany"},{"name":"Institute of Heart Diseases, Wroc\u0142aw Medical University , Borowska 213, 50-556 Wroc\u0142aw , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Michigan School of Medicine , Ann Arbor, MI 48109 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6412-7989","authenticated-orcid":false,"given":"Darren K","family":"McGuire","sequence":"additional","affiliation":[{"name":"The Division of Cardiology, University of Texas Southwestern Medical Center, and Parkland Health and Hospital System , Dallas, TX 75390 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1531-4294","authenticated-orcid":false,"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center Copenhagen , 2730 Herlev , Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen , DK-2200 Copenhagen , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis M","family":"Ruilope","sequence":"additional","affiliation":[{"name":"Cardiorenal Translational Laboratory and Hypertension Unit, Institute of Research imas12 , s\/n, 28041, Madrid , Spain"},{"name":"CIBER-CV, Hospital Universitario 12 de Octubre , s\/n, 28041, Madrid , Spain"},{"name":"Faculty of Sport Sciences, European University of Madrid , s\/n, 28670, Villaviciosa de Od\u00f3n, Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7683-4720","authenticated-orcid":false,"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Baylor Scott and White Research Institute , Dallas, TX 75204 , USA"},{"name":"The Department of Medicine, University of Mississippi School of Medicine , Jackson, MS 39216 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa A","family":"Jankowska","sequence":"additional","affiliation":[{"name":"Institute of Heart Diseases, Wroc\u0142aw Medical University , Borowska 213, 50-556 Wroc\u0142aw , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5547-5084","authenticated-orcid":false,"given":"Erin D","family":"Michos","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Johns Hopkins University School of Medicine , Baltimore, MD 21287 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8364-3447","authenticated-orcid":false,"given":"Dimitrios","family":"Farmakis","sequence":"additional","affiliation":[{"name":"Statistics and Data Insights, University of Cyprus Medical School , Nicosia 2029 , Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo E","family":"Farjat","sequence":"additional","affiliation":[{"name":"Research and Development, Statistics and Data Insights, Bayer PLC , Reading, RG2 6AD , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3425-7528","authenticated-orcid":false,"given":"Peter","family":"Kolkhof","sequence":"additional","affiliation":[{"name":"Research and Development, Cardiovascular Precision Medicines, Bayer AG , 42117, Wuppertal , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Scalise","sequence":"additional","affiliation":[{"name":"Pharmaceutical Development, Bayer Hispania, S.L. , 08970 Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Joseph","sequence":"additional","affiliation":[{"name":"Cardiology and Nephrology Clinical Development, Bayer AG , Berlin 13353 , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George L","family":"Bakris","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Chicago Medicine , Chicago, IL 60637 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Richard L. Roudebush VA Medical Center and Indiana University , Indianapolis, IN 46202 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,17]]},"reference":[{"key":"2022121510271711400_bib1","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2022121510271711400_bib2","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1055\/a-1508-3912","article-title":"Prevalence of atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease in patients with type 2 diabetes mellitus: a primary care research network-based study","volume":"130","author":"Goderis","year":"2022","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2022121510271711400_bib3","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"key":"2022121510271711400_bib4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2337\/dbi19-0038","article-title":"Linking kidney and cardiovascular complications in diabetes-impact on prognostication and treatment: the 2019 Edwin Bierman award lecture","volume":"70","author":"Rossing","year":"2021","journal-title":"Diabetes"},{"key":"2022121510271711400_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdiacomp.2018.11.001","article-title":"Targeting inflammation to reduce ASCVD in type 2 diabetes","volume":"33","author":"Jialal","year":"2019","journal-title":"J Diabetes Complications"},{"key":"2022121510271711400_bib6","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/ki.2010.536","article-title":"Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts","volume":"79","author":"van der Velde","year":"2011","journal-title":"Kidney Int"},{"key":"2022121510271711400_bib7","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"key":"2022121510271711400_bib8","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jdiacomp.2019.04.004","article-title":"Incremental risk of cardiovascular disease and\/or chronic kidney disease for future ASCVD and mortality in patients with type 2 diabetes mellitus: ACCORD trial","volume":"33","author":"Branch","year":"2019","journal-title":"J Diabetes Complications"},{"key":"2022121510271711400_bib9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017","volume":"17","author":"Einarson","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"2022121510271711400_bib10","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2022121510271711400_bib11","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","article-title":"Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"143","author":"Filippatos","year":"2021","journal-title":"Circulation"},{"key":"2022121510271711400_bib12","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2022121510271711400_bib13","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2022121510271711400_bib14","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1161\/CIRCULATIONAHA.116.022194","article-title":"Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus - Mechanisms, management, and clinical considerations","volume":"133","author":"Low Wang","year":"2016","journal-title":"Circulation"},{"key":"2022121510271711400_bib15","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1002\/sim.8282","article-title":"Mixed-effects models for slope-based endpoints in clinical trials of chronic kidney disease","volume":"38","author":"Vonesh","year":"2019","journal-title":"Stat Med"},{"key":"2022121510271711400_bib16","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/eurjpc\/zwaa147","article-title":"Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017","volume":"28","author":"Bragazzi","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2022121510271711400_bib17","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.2337\/dc19-2137","article-title":"The impact of cardiovascular disease and chronic kidney disease on life expectancy and direct medical cost in a 10-year diabetes cohort study","volume":"43","author":"Wan","year":"2020","journal-title":"Diabetes Care"},{"key":"2022121510271711400_bib18","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2022121510271711400_bib19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","article-title":"Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Wheeler","year":"2021","journal-title":"Lancet Diabet Endocrinol"},{"key":"2022121510271711400_bib20","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3390\/jcm9040947","article-title":"GLP-1 receptor agonists and diabetic kidney disease: a call of attention to nephrologists","volume":"9","author":"G\u00f3rriz","year":"2020","journal-title":"J Clin Med"},{"key":"2022121510271711400_bib21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease","volume":"137","author":"Wanner","year":"2018","journal-title":"Circulation"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvac054\/47470948\/pvac054.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/9\/1\/85\/47913637\/pvac054.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/9\/1\/85\/47913637\/pvac054.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T21:57:46Z","timestamp":1671141466000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/9\/1\/85\/6762213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,17]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,10,17]]},"published-print":{"date-parts":[[2022,12,15]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvac054","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1]]},"published":{"date-parts":[[2022,10,17]]}}}